Adage Capital Partners Gp, L.L.C. Rhythm Pharmaceuticals, Inc. Transaction History
Adage Capital Partners Gp, L.L.C.
- $56.4 Billion
- Q2 2025
A detailed history of Adage Capital Partners Gp, L.L.C. transactions in Rhythm Pharmaceuticals, Inc. stock. As of the latest transaction made, Adage Capital Partners Gp, L.L.C. holds 341,000 shares of RYTM stock, worth $33.7 Million. This represents 0.04% of its overall portfolio holdings.
Number of Shares
341,000Holding current value
$33.7 Million% of portfolio
0.04%Shares
6 transactions
Others Institutions Holding RYTM
# of Institutions
246Shares Held
64MCall Options Held
210KPut Options Held
575K-
Black Rock Inc. New York, NY6.74MShares$666 Million0.01% of portfolio
-
Baker Bros. Advisors LP New York, NY5.6MShares$554 Million3.59% of portfolio
-
Ra Capital Management, L.P. Boston, MA5.56MShares$550 Million7.68% of portfolio
-
Primecap Management CO Pasadena, CA4.88MShares$482 Million0.25% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.59MShares$355 Million0.0% of portfolio
About RHYTHM PHARMACEUTICALS, INC.
- Ticker RYTM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,720,000
- Market Cap $5.51B
- Description
- Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convert...